Circulating tumor cells as liquid biopsy markers in cancer patients
Standard
Circulating tumor cells as liquid biopsy markers in cancer patients. / Smit, Daniel J.; Pantel, Klaus.
In: MOL ASPECTS MED, Vol. 96, 101258, 04.2024, p. 101258.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Circulating tumor cells as liquid biopsy markers in cancer patients
AU - Smit, Daniel J.
AU - Pantel, Klaus
PY - 2024/4
Y1 - 2024/4
N2 - Over the past decade, novel methods for enrichment and identification of cancer cells circulating in the blood have been established. Blood-based detection of cancer cells and other tumor-associated products can be summarized under the term of Liquid Biopsy. Circulating tumor cells (CTCs) have been used for diagnosis, risk stratification and treatment selection as well as treatment monitoring in several studies over the past years, thus representing a valuable biomarker for cancer patients. A plethora of methods to enrich, detect and analyze CTCs has been established. In contrast to other liquid biopsy analytes (e.g. ctDNA), CTCs represent a viable analyte that provides a unique opportunity to understand the underlaying biology of cancer and the metastatic cascade on the molecular level. In this review, we provide an overview on the current methods used for enrichment, detection, molecular and functional characterization of CTCs.
AB - Over the past decade, novel methods for enrichment and identification of cancer cells circulating in the blood have been established. Blood-based detection of cancer cells and other tumor-associated products can be summarized under the term of Liquid Biopsy. Circulating tumor cells (CTCs) have been used for diagnosis, risk stratification and treatment selection as well as treatment monitoring in several studies over the past years, thus representing a valuable biomarker for cancer patients. A plethora of methods to enrich, detect and analyze CTCs has been established. In contrast to other liquid biopsy analytes (e.g. ctDNA), CTCs represent a viable analyte that provides a unique opportunity to understand the underlaying biology of cancer and the metastatic cascade on the molecular level. In this review, we provide an overview on the current methods used for enrichment, detection, molecular and functional characterization of CTCs.
U2 - 10.1016/j.mam.2024.101258
DO - 10.1016/j.mam.2024.101258
M3 - SCORING: Review article
C2 - 38387225
VL - 96
SP - 101258
JO - MOL ASPECTS MED
JF - MOL ASPECTS MED
SN - 0098-2997
M1 - 101258
ER -
